GSE216679 Reduced CD8 T cell exhaustion in DR4 risk subjects is selectively augmented with therapy [CD8s]
Contributors : S A Long ; Virginia S Muir ; Britta E Jones ; Valerie Z Wall ; Katharina Lambert ; Alyssa Ylescipidez ; Stephan Pribitzer ; Jerill Thorpe ; Bryce Fuchs ; Alice E Wiedeman ; Megan Tatum ; Hannes Uchtenhagen ; Cate Speake ; Bernard Ng ; Alexander T Heubeck ; Troy R Torgerson ; Adam K Savage ; Michael A Maldonado ; Neelanjana Ray ; Vadim Khaychuk ; Jinqi Liu ; Peter S Linsley ; Jane H BucknerSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensExhausted CD8 T cells (TEX) are associated with worse outcome in cancer yet better outcome in autoimmunity. However, factors...
Source: GEO: Gene Expression Omnibus - June 30, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
GSE216678 Reduced CD8 T cell exhaustion in DR4 risk subjects is selectively augmented with therapy [whole blood]
Contributors : S A Long ; Virginia S Muir ; Britta E Jones ; Valerie Z Wall ; Katharina Lambert ; Alyssa Ylescipidez ; Stephan Pribitzer ; Jerill Thorpe ; Bryce Fuchs ; Alice E Wiedeman ; Megan Tatum ; Hannes Uchtenhagen ; Cate Speake ; Bernard Ng ; Alexander T Heubeck ; Troy R Torgerson ; Adam K Savage ; Michael A Maldonado ; Neelanjana Ray ; Vadim Khaychuk ; Jinqi Liu ; Peter S Linsley ; Jane H BucknerSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensExhausted CD8 T cells (TEX) are associated with worse outcome in cancer yet better outcome in autoimmunity. However, factors...
Source: GEO: Gene Expression Omnibus - June 30, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Medication ‐related osteonecrosis of the jaw leading to sepsis in a patient with rheumatoid arthritis: A case report and clinical implications
(A –I) Computed tomography of the right mandible. Imaging reveals a large area of bone destruction with irregular borders and heterogeneous densities involving the body and ramus of the mandible. The affected bone appears to be sclerotic and fragmented, with areas of sequestration and periosteal reac tion. There is also evidence of soft tissue swelling and abscess formation. Key Clinical MessageChronic use of bisphosphonates, in combination with immunosuppressive therapy, increases the risk of jaw osteonecrosis. When sepsis occurs in patients receiving bisphosphonate, osteonecrosis of the jaw should be considered a poten...
Source: Clinical Case Reports - June 17, 2023 Category: General Medicine Authors: K. Iwasaki,
A. Okazaki Tags: CASE IMAGE Source Type: research
Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries
Patients with rheumatoid arthritis (RA) have an increased risk of infection and malignancy compared with the general population. Infection risk is increased further with the use of disease-modifying antirheuma... (Source: Arthritis Research and Therapy)
Source: Arthritis Research and Therapy - June 12, 2023 Category: Rheumatology Authors: Alyssa Dominique, Merete Lund Hetland, Axel Finckh, Jacques-Eric Gottenberg, Florenzo Iannone, Roberto Caporali, Tzuyung Douglas Kou, Dan Nordstrom, Maria Victoria Hernandez, Carlos S ánchez-Piedra, Fernando Sánchez-Alonso, Karel Pavelka, T. Christopher Tags: Research Source Type: research
Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil
Graft-versus-host disease (GVHD) has been the major complication limiting success of allogeneic hematopoietic cell transplantation since the field began 70 years ago. The standard regimen to prevent GVHD, a combination of calcineurin inhibitor and methotrexate, has been used since the 1980s, but it has significant tissue toxicity and does not decrease the risk of chronic GVHD (reviewed in 1). The drug abatacept was approved by the FDA for the prevention of acute GVHD in 2021, however it also does not address the risk of chronic GVHD. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 11, 2023 Category: Hematology Authors: Najla El Jurdi, Alex Hoover, Daniel O'Leary, Qing Cao, Ashish Gupta, Christen Ebens, Joseph E. Maakaron, Brian C. Betts, Armin Rashidi, Mark B. Juckett, Troy Lund, Veronika Bachanova, Margaret L MacMillan, Jeffrey S. Miller, Paul J. Orchard, John E. Wagne Source Type: research
Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil
Graft-versus-host disease (GVHD) has been the major complication limiting the success of allogeneic (allo-) hematopoietic cell transplantation (HCT) since advent of the procedure some 70 years ago. The standard GVHD preventive regimen, a combination of a calcineurin inhibitor and methotrexate, has been used since the 1980s, but it is associated with significant tissue toxicity and does not decrease the risk of chronic GVHD [1]. Abatacept was approved by the US Food and Drug Administration for the prevention of acute GVHD in 2021; however, this approval does not address the risk of chronic GVHD [2]. (Source: Biology of Bloo...
Source: Biology of Blood and Marrow Transplantation - June 11, 2023 Category: Hematology Authors: Najla El Jurdi, Alex Hoover, Daniel O'Leary, Qing Cao, Ashish Gupta, Christen Ebens, Joseph E. Maakaron, Brian C. Betts, Armin Rashidi, Mark B. Juckett, Troy Lund, Veronika Bachanova, Margaret L MacMillan, Jeffrey S. Miller, Paul J. Orchard, John E. Wagne Tags: Allogeneic - Adult Source Type: research
Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review
CONCLUSION: Both types of the mRNA-vaccines and the AstraZeneca COVID-19 vaccines are highly effective and safe in patients with ARD. However, due to their suboptimal response in some patients, alternative mitigation strategies such as booster vaccines and shielding practices should also be followed. Management of immunomodulatory treatment regimens during the peri vaccination period should be individualized through shared decision making with patients and their attending rheumatologists.PMID:37244811 | PMC:PMC10201317 | DOI:10.1016/j.vaccine.2023.05.048 (Source: Vaccine)
Source: Vaccine - May 27, 2023 Category: Allergy & Immunology Authors: Anwar I Joudeh Abdu Qaid Lutf Salah Mahdi Gui Tran Source Type: research
Benefits of Autoantibody Enrichment in Early Rheumatoid Arthritis: Analysis of Efficacy Outcomes in Four Pooled Abatacept Trials
ConclusionsThis analysis, including large patient numbers of early-RA abatacept trials, confirmed beneficial treatment effects of abatacept in patients with SPEAR versus non-SPEAR. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - May 25, 2023 Category: Rheumatology Source Type: research
19 The inflammation in the pathology of patients with mucopolysaccharidosis
Conclusions
These results provide the rational for individual treatment trials (ITTs) with the aim to evaluate immunomodulatory molecules, repurposed in MPS. Furthermore, they will – together with the results of the ITTs – be utilized for the development of a decision tool for the personalized treatment of unmet clinical needs in these patients. (Source: Archives of Disease in Childhood)
Source: Archives of Disease in Childhood - May 18, 2023 Category: Pediatrics Authors: Wiesinger, A.-M., Lagler, F., Bigger, B., Kampmann, C., Giugliani, R., Scarpa, M. Tags: General abstracts Source Type: research
Monogenic inborn errors of immunity in autoimmune disorders
In conclusion, 50% of children with AID have underlying PIRD.LRBA deficiency andSTAT1 GOF were the most common PIRD. Age at presentation, number of autoimmunity, routine immunological tests, and JMF criteria are not predictive of underlying PIRD. Early diagnosis with exome sequencing alters the prognosis and opens new therapeutic avenue. (Source: Immunologic Research)
Source: Immunologic Research - May 18, 2023 Category: Allergy & Immunology Source Type: research
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries
Conclusion
Uptake of newer b/tsDMARDs occurred mainly in biologic-experienced patients. Regardless of mode of action, only a minority of patients starting a second or later b/tsDMARD course remained on drug and achieved LDA. Superior outcomes for adalimumab indicate that the positioning of newer b/tsDMARDs in the PsA treatment algorithm remains to be established. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - May 11, 2023 Category: Rheumatology Authors: Glintborg, B., Di Giuseppe, D., Wallman, J. K., Nordström, D. C., Gudbjornsson, B., Hetland, M. L., Askling, J., Grondal, G., Sokka, T., Provan, S. A., Michelsen, B., Kristianslund, E. K., Dreyer, L., Love, T. J., Lindström, U. Tags: Editor's choice, ARD Lay summaries, ARD, Psoriatic arthritis Source Type: research
Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing
Conclusions
We identified new shared risk loci with functional impact in vasculitis and pinpointed potential causal genes, some of which could represent promising targets for the treatment of vasculitis. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - May 11, 2023 Category: Rheumatology Authors: Ortiz-Fernandez, L., Carmona, E. G., Kerick, M., Lyons, P., Carmona, F. D., Lopez Mejias, R., Khor, C. C., Grayson, P. C., Tombetti, E., Jiang, L., Direskeneli, H., Saruhan-Direskeneli, G., Callejas-Rubio, J.-L., Vaglio, A., Salvarani, C., Hernandez-Rodri Tags: Open access, ARD, Vasculitis Source Type: research
Non ‐Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN‐101)
ConclusionBoth CD28 and ICOS signaling play critical roles in inflammatory arthritis. Therapeutic agents such as acazicolcept that coinhibit both ICOS and CD28 signaling may mitigate inflammation and/or disease progression in RA and PsA more effectively than inhibitors of either pathway alone. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - May 10, 2023 Category: Rheumatology Authors: Stacey R. Dillon,
Lawrence S. Evans,
Katherine E. Lewis,
Susan Debrot,
Tiffany C. Blair,
Sherri Mudri,
Kayla Kleist,
Steven D. Levin,
Janhavi G. Bhandari,
Logan Garrett,
Martin F. Wolfson,
Pamela M. Holland,
Mark W. Rixon,
Stanford L. Peng Tags: Full Length Source Type: research
Abatacept as salvage therapy for life-threatening refractory autoimmune hemolytic anemia: a case report
Hematology. 2023 Dec;28(1):2208010. doi: 10.1080/16078454.2023.2208010.ABSTRACTAutoimmune hemolytic anemia (AIHA) can be life-threatening, if hemoglobin (Hb) levels continue to decline after established treatments with glucocorticoids, rituximab, intravenous immunoglobulins, and plasmapheresis. Impaired regulatory T cells (Treg) are proposed to alleviate AIHA development through decreased binding of CTLA-4 to antigen-presenting cells. Abatacept is a fusion protein with a CTLA-4 domain and is approved for use in rheumatoid arthritis. It mimics the immunosuppressive CTLA-4 effect of Treg. Thus, application of abatacept in re...
Source: Hematology - May 3, 2023 Category: Hematology Authors: Joerg Hoffmann Georg Schliesser Andreas Neubauer Source Type: research
